Overview
Compare with Prime Medicine, Inc., CG Oncology, Inc. or Zeo ScientifiX, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$39.8M
Out of $4.4M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $4.4M | $4.1M |
| Research and development | $39.8M | $32.1M |
| General and administrative | $27.6M | $26.7M |
| Total operating expenses | $67.3M | $58.8M |
| Loss from operations | -$62.9M | -$54.8M |
| Interest income | $922.0K | $1.3M |
| Interest expense | -$5.2M | -$688.0K |
| Other (expense) income, net | -$664.0K | $140.0K |
| Total other (expense) income | -$4.9M | $703.0K |
| Net loss | -$67.8M | -$54.1M |
| Foreign currency translation adjustment | $13.0K | $28.0K |
| Comprehensive loss | -$67.8M | -$54.0M |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2024-07-31 |
|---|---|---|---|
| Cash | $18.6M | $58.5M | |
| Prepaid expenses and other current assets | $5.8M | $3.2M | |
| Total current assets | $24.3M | $61.7M | |
| Property and equipment, net | $14.4M | $16.6M | |
| Restricted cash | $316.0K | $307.0K | |
| Other assets | $4.5M | $3.9M | |
| Total assets | $43.5M | $82.4M | |
| Accounts payable | $6.2M | $4.2M | |
| Accrued expenses and other current liabilities | $14.7M | $15.5M | |
| Operating lease obligations | $858.0K | $519.0K | |
| Current portion of long term debt | $1.2M | $1.3M | |
| Total current liabilities | $23.0M | $21.6M | |
| Operating lease obligations, less current portion | $3.5M | $3.3M | |
| Long term debt, net | $27.5M | $27.3M | |
| Other non-current liabilities | $1.6M | $564.0K | |
| Total non-current liabilities | $32.6M | $31.2M | |
| Total liabilities | $55.7M | $52.8M | |
| Series B Convertible Preferred Stock; zero shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock; $0.01 par value; 390,000,000 shares authorized; 312,501,472 and 291,489,058 shares issued, and 312,379,972 and 291,367,558 shares outstanding at December 31, 2025 and 2024, respectively | $3.1M | $2.9M | |
| Treasury stock, at cost, 121,500 shares at December 31, 2025 and 2024 | -$48.0K | -$48.0K | |
| Additional paid-in capital | $392.8M | $366.9M | |
| Accumulated other comprehensive income | $61.0K | $48.0K | |
| Accumulated deficit | -$408.1M | -$340.2M | |
| Total stockholders' equity | -$12.2M | $29.6M | |
| Total liabilities and stockholders' equity | $43.5M | $82.4M | |
| Convertible preferred stock, par value (in USD per share) | $0.01 | $0.01 | $0.01 |
| Convertible preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | 10.0M shares |
| Convertible preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Convertible preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in USD per share) | $0.01 | $0.01 | $0.01 |
| Common stock, shares authorized (in shares) | 390.0M shares | 390.0M shares | 390.0M shares |
| Common stock, shares issued (in shares) | 312.5M shares | 291.5M shares | |
| Common stock, shares outstanding (in shares) | 312.4M shares | 291.4M shares | |
| Treasury stock (in shares) | 121.5K shares | 121.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$67.8M | -$54.1M |
| Depreciation and amortization expense | $2.4M | $2.0M |
| Amortization of Debt Issuance Costs | $1.4M | $16.0K |
| Non-cash interest expense | $100.0K | $100.0K |
| Non-cash lease expense | $1.3M | $856.0K |
| Non-cash expense (income) from collaborative arrangements, net | -$2.5M | -$2.2M |
| Stock-based compensation expense | $7.7M | $7.4M |
| Other | $1.0M | $37.0K |
| Prepaid expenses and other current assets | -$2.6M | $361.0K |
| Accounts payable and accrued expenses | $3.3M | $4.1M |
| Lease obligations | -$1.2M | -$833.0K |
| Net cash used in operating activities | -$57.0M | -$42.1M |
| Purchases of property and equipment | -$185.0K | -$3.4M |
| Payment of security deposits | -$126.0K | $0 |
| Net cash (used in) provided by investing activities | -$311.0K | -$3.4M |
| Proceeds from issuance of common stock | $19.9M | $38.6M |
| Payment of equity issuance costs | -$1.5M | -$2.9M |
| Proceeds from issuance of debt | $0 | $30.0M |
| Payments of debt issuance costs | $0 | -$809.0K |
| Payment of EB-5 loan | -$1.0M | $0 |
| Net cash provided by financing activities | $17.3M | $64.9M |
| Effect of changes in exchange rate on cash and restricted cash | $13.0K | $28.0K |
| Net (decrease) increase in cash and restricted cash | -$39.9M | $19.4M |
| Right-of-use assets related to operating leases | $1.3M | $103.0K |
| Series B Convertible Preferred Stock reacquisition | $0 | -$1.0K |
| Issuance of common stock for Avenue Capital agreement | $0 | $1.0M |
Leadership
Who has led Ocugen, and when. Pick a name to see everywhere that person has worked.
Board members and other officers (1)
- Senior vice presidentNirdosh Jagota1
Former names
- HISTOGENICS CORPAug 7, 2006 to Sep 26, 20194
Recent filings
- Oct 15, 20268-K
- Oct 15, 20268-K
- Oct 13, 20264
- Oct 9, 2026144
- Oct 6, 20268-K
- Sep 23, 20268-K
- Sep 11, 20264
- Sep 9, 2026144
- Sep 8, 20268-K
- Aug 14, 2026DEFA14A
- Aug 13, 2026SCHEDULE 13G/A
- Aug 7, 2026SCHEDULE 13G
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jul 30, 2026DEF 14A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websiteocugen.com1
- X (Twitter)x.com/ocugen1
- LinkedInwww.linkedin.com/company/ocugen1
- WikidataQ106698278
- SEC EDGARCIK 1372299
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataOcugen on Wikidata
- 2SEC EDGAROcugen filings on SEC EDGAR
- 3Company websiteOcugen logo
- 4SEC EDGAROcugen filings on SEC EDGAR
- 5SEC EDGAROcugen 10-K for fiscal 2025
- 6SEC EDGAROcugen 10-K for fiscal 2019
- 7SEC EDGAROcugen 10-K for fiscal 2022
- 8SEC EDGAROcugen 10-K for fiscal 2023
- 9SEC EDGAROcugen 10-K for fiscal 2021
- 10SEC EDGAROcugen 10-Q for fiscal 2026
- 11SEC EDGAROcugen 10-Q for fiscal 2026
- 12SEC EDGAROcugen 10-K for fiscal 2019